DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: Vulvar Cancers

Y Chae;L Corthell;S Patel;R Edwards;J Scalici;H Kim;L Il-Young Chung;M Othus;C McLeod;H Chen;E Sharon;H Streicher;C Ryan;C Blanke;R Kurzrock Clinical Cancer Research Jan 17;31(2):308-315

PMid: PMID39561273 | PMC number: PMC11804806

Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Metastatic Basal Cell Carcinoma

S Patel;E Cano-Linson;Y Chae;S Schokrpur;C Lao;B Powers;A Victor;A Onitilo;S Shin;N Takebe;S Threlkel;C McLeod;H Chen;E Sharon;M Othus;C Ryan;C Blanke;R Kurzrock NPJ Precision Oncology

PMid: PMID39856213 | PMC number: PMC11759674

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: Pancreatic Neuroendocrine Neoplasm (PNEN) Cohort

S Patel;J Fisher;Y Chae;L Soto;A Kasi;B Konda;M Walshauser;E Parra;J Zhang;C Duault;E Gonzalez-Kozlova;G Manyam;T Holmes;J Zhang;H Chen;D Duose;C Laberiano Fernandez;R Luthra;G Al-Atrash;S Kim-Schulze;H Maecker;I Wistuba;S Gnjatic;J Lee;J Zhang;C Magner;H Chen;E Sharon;M Othus;C Ryan;C Blanke;C Haymaker;R Kurzrock Journal for ImmunoTherapy of Cancer

PMid: PMID40588371 | PMC number: PMC12211841

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: Vaginal Cancers

Y Chae;J Czeskleba;S Patel;A Menter;W Robinson;N Jones;M Rampurwala;A Naing;J Beck;C Moloney;L Chung;C McLeod;H Chen;E Sharon;S Threlkel;M Othus;C Ryan;C Blanke;R Kurzrock AACR 2025 Meeting, poster; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT092

Efficacy and Toxicity of Nivolumab and Ipilimumab in Rare Cancer Brain Metastases: A Multi-Center Basket Trial Analysis (NCI/SWOG S1609)

M Ahluwalia;S Solomon;S Patel;S Sarfraz;M Othus;Y Chae;R Kurzrock ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), poster; Abstract # 2619 Poster Bd # 266

A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort

YK Chae;M Othus;S Patel;R Aljumaly;K Win;T Pejovic;S Thomas;W Robinson;H Kim;I Chung;C McLeod;H Chen;E Sharon;H Streicher;C Ryan;C Blanke;R Kurzrock Cancer Communications Aug;45(8):976-986

PMid: PMID40402690 | PMC number: PMC12365539

First cycle toxicity and survival in patients with rare cancers treated with checkpoint inhibitors

M Othus;S Patel;Y Chae;E Dietrich;H Streicher;E Sharon;R Kurzrock Journal of the National Cancer Institute Apr 1;117(4):692-700

PMid: PMID39565908 | PMC number: PMC11972677

A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 48) in Patients with Advanced Gallbladder Cancer

S Patel;E Guadarrama;Y Chae;M Dennis;B Powers;C-Y Liao;W Ferri;T George;E Sharon;C Ryan;M Othus;G Lopez;C Blanke;R Kurzrock Cancer Sep 1;130(17):2918-2927

PMid: PMID38358334 | PMC number: PMC11309904

A phase II basket trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic neoplasia

S Patel;M Othus;Y Chae;M Dennis;S Gordon;D Mutch;W Samlowski;W Robinson;E Sharon;C Ryan;G Lopez;M Plets;C Blanke;R Kurzrock Clinical Cancer Research Jan 5;30(1):33-38

PMid: PMID37882676 | PMC number: PMC10842092

SWOG/NCI S1609 Phase II Basket Trial Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART): Non-Epithelial Ovarian Cancer

Y Chae;M Othus;S Patel;K Wilkinson;E Whitman-Purves;J Lea;J Schallenkamp;N Adra;L Appleman;M Alden;J Thomes Pepin;J Ellerton;A Poklepovic;A Walter;M Rampurwala;W Robinson;L Il-Young Chung;H Kim;C McLeod;G Lopez;H Chen;E Sharon;H Streicher;C Ryan;C Blanke;R Kurzrock Clinical Cancer Research Oct 17. doi: 10.1158/1078-0432.CCR-24-0606. Online ahead of print

PMid: PMID39417692

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: Sarcomatoid Lung Cohort #11

Y Chae;M Othus;S Patel;P Sandhu;L Corum;J Cetnar;S Rayani;L Il-Young Chung;C McLeod;H Chen;E Sharon;H Streicher;C Ryan;C Blanke;R Kurzrock AACR Annual Meeting (April 5-10, 2024, San Diego, CA), poster

Phase II Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG/NCI Experience: Invasive Mucinous or Non-mucinous Lepidic Adenocarcinoma of the Lung (Formerly Bronchioloalveolar Carcinoma)

Y Chae;M Othus;S Patel;D Gerber;T Tanvetyanon;L Il-Young Chung;H Kim;C McLeod;G Lopez;H Chen;E Sharon;H Streicher;C Ryan;C Blanke;R Kurzrock Therapeutic Advances in Medical Oncology Nov 22:16:17588359241293401

PMid: PMID39583952 | PMC number: PMC11583498

Decoding biomarkers of immune activation in neuroendocrine carcinomas treated with ipilimumab and nivolumab using a multiomic approach

C Haymaker;G Kumar;Y Chae;E Gonzalez-Koslova;C Dualt;J Zhang;M Othus;L Soto;G Manyam;P Jiang;E Cuentas;C Fernandez;A Reuben;H Maecker;S Gnjatic;G al-Atrash;J Zhang;J Lee;S Patel;R Kurzrock ESMO Sarcoma and Rare Cancers Congress (March 14-16, 2024 Lugano, Switzerland), poster

Correlations Between First Cycle Toxicity and Overall Survival in Patients with Rare Cancers Treated with Immune Checkpoint Inhibitors (NCI/SWOG S1609)

M Othus;S Patel;YK Chae;E Dietrich;H Streicher;E Sharon;R Kurzrock ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster;J Clin Oncol 42, 2024 (suppl 16; abstr 2655)

Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial

M Othus;S Patel;YK Chae;E Deitrich;H Streicher;E Sharon;R Kurzrock JNCI-Journal of the National Cancer Institute May 8;116(5):673-680

PMid: PMID38243705 | PMC number: PMC11077308

Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609)

Y Chae;E Dietrich;M Othus;L Il-Young Chung;H Kim;C Ryan;CD Blanke;S Patel;R Kurzrock ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), Rapid Oral Abstract Session; J Clin Oncol 42, 2024 (suppl 16; abstr 2514)

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: Adrenocortical Carcinoma Cohort

S Patel;M Othus;Y Chae;T Huynh;B Tan;T Kuzel;N Vogelzang;C McLeod;G Lopez;H Chen;E Sharon;H Streicher;C Ryan;C Blanke;R Kurzrock Journal for ImmunoTherapy of Cancer (JITC) Jul 27;12(7):e009074

PMid: PMID39067873 | PMC number: PMC11284838

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The Desmoid Tumors

Y Chae;M Othus;S Patel;B Powers;C Hsueh;R Govindarajan;S Bucur;H Kim;L Il-Young Chung;C McLeod;H Chen;E Sharon;H Streicher;C Ryan;CD Blanke;R Kurzrock Journal for ImmunoTherapy of Cancer (JITC) Sep 28;12(9):e009128

PMid: PMID39343510 | PMC number: PMC11440191

Correlations Between Baseline Tumor Burden and Overall Survival in Patients with Rare Cancers Treated with Immune Checkpoint Inhibitors (NCI/SWOG S1609)

P Swiecicki;M Othus;S Patel;Y Chae;R Kurzrock SITC (Nov. 6-10, Houston, TX), poster

Outcome and Treatment Toxicity at Community versus Academic Sites for Patients with Rare Cancers on Immune Checkpoint Inhibitors (NCI/SWOG S1609)

J Jawara;L Cavalcante;S Patel;Y Chae;M Othus;R Kurzrock ABRCMS 2024 Graduate Symposium (Nov. 13-16 in Pittsburgh, PA), poster

Change in RECIST Tumor Size Correlates Linearly with Survival in Patients Treated with Checkpoint Inhibitor Therapy (SWOG S1609)

M Othus;S Patel;Y Chae;E Dietrich;H Streicher;E Sharon;R Kurzrock J Clin Oncol 41, 2023 (suppl 16; abstr 2504); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), oral

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The Bronchoalveolar Carcinoma of the Lung (Cohort 12)

Y Chae;M Othus;S Patel;D Gerber;T Tanvetyanon;L Il-Young Chung;C McLeod;H Chen;E Sharon;H Streicher;C Ryan;C Blanke;R Kurzrock WCLC Annual Meeting (September 9-12, 2023, Singapore), poster

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The Desmoid Tumors (Cohort 27)

YK Chae;M Othus;S Patel;B Powers;C-T Hsueh;R Govindarajan;S Bucur;L Il-Young Chung;C McLeod;H Chen;E Sharon;H Streicher;C Ryan;C Blanke;R Kurzrock J Clin Oncol 41, 2023 (suppl 16; abstr 11516); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The Vulvar Cancers

Y Chae;M Othus;S Patel;R Edwards;J Scalici;L Il-Young Chung;C McLeod;H Chen;E Sharon;H Streicher;C Ryan;C Blanke;R Kurzrock J Clin Oncol 41, 2023 (suppl 16; abstr 5517); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The non-epithelial ovarian tumor cohort #13

Y Chae;M Othus;S Patel;K Wilkinson;E Whitman-Purves;J Lea;J Schallenkamp;N Adra;L Appleman;M Alden;J Thomes Pepin;J Ellerton;A Poklepovic;A Walter;M Rampurwala;L Il-Young Chung;C McLeod;H Chen;E Sharon;H Streicher;C Ryan;CD Blanke;R Kurzrock AACR Annual Meeting (April 14-19, 2023, Orlando, FL, poster

A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the clear cell ovarian, endometrial, cervical cancer cohorts

Y Chae;M Othus;S Patel;F Backes;D O'Malley;M Cristea;A Naing;K Kurnit;R Eskander;S Goodrich;L Il-Young Chung;C McLeod;H Chen;E Sharon;H Streicher;C Ryan;CD Blanke;R Kurzrock AACR Annual Meeting (April 14-19, 2023, Orlando, FL, poster

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The small cell carcinoma of the ovary, hypercalcemic type cohort #49

Y Chae;M Othus;S Patel;R Aljumaily;K Win;T Pejovic;S Thomas;L Il-Young Chung;C McLeod;H Chen;E Sharon;H Streicher;C Ryan;CD Blanke;R Kurzrock AACR Annual Meeting (April 14-19, 2023, Orlando, FL, poster

Clinical outcomes and translational analysis of DART S1609: the thyroid cancer cohort; PD-1+ PD-L1+ TIL correlated with favorable survival

YK Chae;Y Lu;S Patel;C Rodriguez;A Onitilo;A Mattour;I Rybkin;S Fenton;L Il-Young Chung;H Kim;M Othus;E Parra;J Zhang;L Gomez;C Fernandez;L Soto;H Chen;G Manyam;D Duose;R Luthra;J Zhang;G Al-Atrash;I Wistuba;J Lee;J Zhang;C Haymaker;C McLeod;H Chen;E Sharon;C Ryan;G Lopez;M Plets;CD Blanke;R Kurzrock SITC Annual Meeting (Nov. 1-5, 2023, San Diego, CA), poster

A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

S Adams;M Othus;S Patel;K Miller;R Chugh;S Schuetze;M Chamberlin;B Haley;A Storniolo;K Cawley;M Reddy;S Anderson;C Zimmerman;A O'Dea;M Mirshahidi;J Ahnert;F Brescia;O Hahn;J Raymond;D Biggs;M Thompson;R Connolly;E Sharon;L Korde;R Gray;E Mayerson;M Plets;CD Blanke;YK Chae;R Kurzrock Clinical Cancer Research, Jan 15;28(2):271-278

PMid: PMID34716198 | PMC number: PMC8776596

A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Disease

S Patel;M Othus;YK Chae;M Dennis;S Gordon;B Tan;W Samlowski;E Sharon;C Ryan;M Plets;CD Blanke;R Kurzrock Society for Immunotherapy of Cancer (SITC) (Nov 8-12,2022, Boston, MA), poster

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-Grade Neuroendocrine Neoplasm Cohort

S Patel;M Othus;YK Chae;J Strosberg;J Wang;B Konda;J Hayward;C McLeod;H Chen;E Sharon;E Mayerson;C Ryan;M Plets;CD Blanke;R Kurzrock Cancer Sep 1;127(17):3194-3201; Apr 21. doi: 10.1002/cncr.33591. Online ahead of print

PMid: PMID33882143 | PMC number: PMC8606104

A Multicenter Phase II Trial (SWOG S1609, Cohort 51) of Ipilimumab and Nivolumab in Metastatic or Unresectable Angiosarcoma: a Sub-Study of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART)

M Wagner;M Othus;S Patel;C Ryan;A Sangal;B Powers;G Budd;A Victor;C-T Hsueh;R Chugh;S Nair;K Leu;M Agulnik;E Sharon;E Mayerson;M Plets;C Blanke;H Streicher;YK Chae;R Kurzrock Journal for Immunotherapy of Cancer, Aug;9(8):e002990. doi: 10.1136/jitc-2021-002990

PMid: PMID34380663 | PMC number: PMC8330584

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

S Patel;M Othus;Y Chae;F Giles;D Hansel;P Singh;A Fontaine;M Shah;A Kasi;T Al Baghdadi;S Vasireddy;E Mayerson;CW Ryan;Melissa Plets;CD Blanke;R Kurzrock Clinical Cancer Research May 15;26(10):2290-2296

PMid: PMID31969335 | PMC number: PMC7231627

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The Small Bowel Cancer Cohort

YK Chae;M Othus;SP Patel;M Zalupski;A Kasi;M Khalil;A Kalyan;B Polite;S Fenton;S Gurung;C McLeod;F Giles;HX Chen;E Sharon;E Mayerson;M Plets;C Ryan;CD Blanke;R Kurzrock American Association for Cancer Research Annual Meeting (April 24-29, 2020, San Diego, CA), oral

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The Salivary Gland Tumor Cohort

YK Chae;M Othus;SP Patel;J Ohr;F Worden;J Suga;A Naing;S Fenton;H Kang;S Gurung;C Mcleod;F Giles;HX Chen;E Sharon;E Mayerson;M Plets;C Ryan;CD Blanke;R Kurzrock American Association for Cancer Research Annual Meeting (April 24-29, 2020, San Diego, CA)

Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Metaplastic Carcinoma of the Breast: DART (SWOG S1609, Cohort 36)

S Adams;M Othus;S Patel;Y Chae;K Miller;R Chugh;S Schuetze;E Sharon;L Korde;R Gray;E Mayerson;M Plets;R Kurzrock J Clin Oncol 38: 2020 (suppl; abstr 1073); American Society of Clinical Oncology 2020 Annual Meeting, poster session

Dual Checkpoint Blockade in a Neuroendocrine Carcinoma with Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden [case report]

J Gong;D Adashek;D Frishberg;M Guan;V Placencio-Hickock;A Gangi;G Gresham;R Tuli;M Othus;YK Chae;R Kurzrock;A Hendifar JCO Precision Oncology May 15;4:PO.18.00391

PMid: PMID33215052 | PMC number: PMC7670562

A multicenter phase II trial (SWOG S1609, Cohort 51) of Ipilimumab and Nivolumab in metastatic or unresectable angiosarcoma: a sub-study of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

M Wagner;M Othus;S Patel;C Ryan;A Sangal;B Powers;GT Budd;A Victor;C-T Hsueh;R Chugh;E Mayerson;M Plets;CD Blanke;H Streicher;YK Chae;R Kurzrock Journal for ImmunoTherapy of Cancer Nov, 8 (Suppl 3) A843; Society for Immunotherapy of Cancer (SITC) Annual Meeting (November 10-15, 2020, virtual), oral presentation

Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response [Response to Letter to Editor]

S Patel;M Othus;YK Chae;R Kurzrock Clinical Cancer Research May 15;26(10):2434

PMid: PMID32414761

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The Thyroid Tumor Cohort

YK Chae;M Othus;SP Patel;S Fenton;D Wang;C Rodriguez;A Onitilo;A Mattour;I Rybkin;J Hayward;C McLeod;H Chen;E Sharon;E Mayerson;CW Ryan;M Plets;CD Blanke;R Kurzrock Journal for ImmunoTherapy of Cancer Nov, 8 (Suppl 3) A288; Society for Immunotherapy of Cancer (SITC) Annual Meeting (November 10-15, 2020, virtual), poster

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) S1609: The Neuroendocrine Cohort

SP Patel;M Othus;YK Chae;FJ Giles;DE Hansel;PP Singh;AC Fontaine;M Shah;AK Kasi;T Al Baghdadi;M Matrana;Z Gatalica;WM Korn;J Hayward;CM McLeod;H Chen;E Sharon;E Mayerson;CW Ryan;M Plets;CD Blanke;R Kurzrock American Association for Cancer Research (March 29-April 3, 2019, Atlanta, GA), accepted 2/8/19, oral presentation

SWOG S1609: A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART)

S Patel;M Othus;Y Chae;F Giles;J Hayward;C McLeod;H Chen;E Sharon;E Mayerson;C Ryan;M Plets;CD Blanke;R Kurzrock J Clin Oncol 37(suppl; abstr TPS2658); ASCO (5/31-6/4/2019, Chicago IL), TIPS, poster session

Trials, Tribulations, and Triumphs in Coordinating a “Not Otherwise Categorized” Cohort in an Umbrella Trial for Rare Cancers

E Mayerson;M Plets;R Kurzrock;YK Chae;S Patel;M Othus Society for Clinical Trials (May 19-22, 2019, New Orleans, LA), oral

Rethinking the Traditions of Trial Design: A Rare Cancer Basket Trial as a Motivating Example

M Plets;E Mayerson;R Kurzrock;YK Chae;S Patel;M Othus Society for Clinical Trials (May 19-22, 2019, New Orleans, LA), oral

Rare cancer research in the National Clinical Trials Network:The SWOG Experience

A Schott European Society for Medical Oncology (October 7-11, 2016, Copenhagen, Denmark), invited oral presentation